Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 114873-06-2
2. Boc-phe(3-me)-oh
3. Boc-3-methy-l-phenylalanine
4. (s)-2-((tert-butoxycarbonyl)amino)-3-(m-tolyl)propanoic Acid
5. Boc-d-phe(3-me)-oh
6. Boc-l-3-methylphenylalanine
7. (2s)-3-(3-methylphenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic Acid
8. Schembl16423
9. Boc-l-3-methyl Phenylalanine
10. Dtxsid00921524
11. L-phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-
12. Zinc2386873
13. Mfcd01862944
14. Akos015836522
15. Akos015895346
16. Ac-9924
17. Am83421
18. Cs-w012282
19. As-14666
20. Boc-phe(3-me)-oh, >=98.0% (tlc)
21. 3-methyl-n-(t-butoxycarbonyl)-l-phenylalanine
22. 73m062
23. A50146
24. N-(tert-butoxycarbonyl)-3-methyl-l-phenylalanine
25. Boc-l-3-methylphenylalanine (boc-l-phe(3-me)-oh)
26. J-003145
27. (s)-2-(tert-butoxycarbonylamino)-3-m-tolylpropanoic Acid
28. N-[tert-butoxy(hydroxy)methylidene]-3-methylphenylalanine
29. (2s)-2-{[(tert-butoxy)carbonyl]amino}-3-(3-methylphenyl)propanoic Acid
Molecular Weight | 279.33 g/mol |
---|---|
Molecular Formula | C15H21NO4 |
XLogP3 | 2.5 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 6 |
Exact Mass | 279.14705815 g/mol |
Monoisotopic Mass | 279.14705815 g/mol |
Topological Polar Surface Area | 75.6 Ų |
Heavy Atom Count | 20 |
Formal Charge | 0 |
Complexity | 348 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Details:
Funding supports aclipse therapeutics’ and sheffield institute of translational neuroscience’s development of M102 in amyotrophic lateral sclerosis. M102 is Aclipse’s drug candidate for the treatment of amyotrophic lateral sclerosis.
Lead Product(s): M102
Therapeutic Area: Neurology Brand Name: M102
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Medical Research Council (U.K)
Deal Size: $2.2 million Upfront Cash: Undisclosed
Deal Type: Funding January 26, 2021
Lead Product(s) : M102
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Medical Research Council (U.K)
Deal Size : $2.2 million
Deal Type : Funding
Aclipse Therapeutics Announces $2.2 Million Grant from UK’s Medical Research Council for Develop...
Details : Funding supports aclipse therapeutics’ and sheffield institute of translational neuroscience’s development of M102 in amyotrophic lateral sclerosis. M102 is Aclipse’s drug candidate for the treatment of amyotrophic lateral sclerosis.
Brand Name : M102
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 26, 2021
Details:
The grant will support the translational development of M102, a drug candidate for the treatment of amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND) or Lou Gehrig's disease.
Lead Product(s): M102
Therapeutic Area: Neurology Brand Name: M102
Study Phase: PreclinicalProduct Type: Undisclosed
Sponsor: FightMND
Deal Size: $0.7 million Upfront Cash: Undisclosed
Deal Type: Funding September 29, 2020
Lead Product(s) : M102
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : FightMND
Deal Size : $0.7 million
Deal Type : Funding
Aclipse Therapeutics Awarded AUD 1 Million Grant from FightMND
Details : The grant will support the translational development of M102, a drug candidate for the treatment of amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND) or Lou Gehrig's disease.
Brand Name : M102
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
September 29, 2020
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?